The Latest Cardiac and Vascular News
Company’s first female executive to lead commercialization efforts of BIOLIFE4D’s live-saving 3D bioprinting technologies CHICAGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it […]
Birla co-published paper with Stuart K. Williams, a renowned industry figure, to highlight 3D bioprinting’s impact on cardiac failure treatment CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs […]
Pioneering biotech company reaches significant milestone, using proprietary bioink to successfully 3D bioprint a mini-heart with full structure of a whole heart, including chambers and ventricles CHICAGO, Sept. 09, 2019 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue […]
CHICAGO, June 25, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint human cardiac tissue – specifically, a […]
CHICAGO, Jan. 02, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Dr. Ravi Birla as its Chief Science Officer. Birla previously served as […]
CHICAGO, Oct. 13, 2017 /PRNewswire/ — Bioprinting startup BIOLIFE4D named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as Chief Medical Officer, further bolstering its world-class leadership team. BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to […]
CHICAGO, Sept. 7, 2017 /PRNewswire/ — BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. […]
